FDA
No application listedNo application naming retatrutide as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDARetatrutide: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is Retatrutide?
Retatrutide (LY3437943) is a 39-residue lipidated peptide with a C20 fatty diacid chain that targets the GIP, GLP-1 and glucagon receptors. It is an investigational compound with no marketing authorisation recorded in the databases checked (see regulatory status). This page covers chemistry and regulatory status only.
What are the chemical facts for Retatrutide?
- Name
- Retatrutide
- Also written
- LY3437943
- Sequence
- 39-residue lipidated peptide (C20 diacid)
- Length
- 39 residues (as described)
- Molecular formula
C221H342N46O68- Average molecular weight
- 4731 g/mol
- CAS number
2381089-83-2(confirmed in PubChem)- PubChem
- CID 171390338
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of Retatrutide?
- A 2026 analytical paper describes retatrutide as a long-acting triple incretin receptor agonist that targets GLP-1R, GIPR and the glucagon receptor, and reports its detection in human plasma and urine by LC-HRMS.[1]
- A 2026 paper compared semaglutide, tirzepatide and retatrutide in human kidney cells and in mouse models of renal fibrosis and ageing.[2]
Receptor and pathway background: Incretin and glucagon receptors.
What has published research on Retatrutide looked at?
2 studies are cited for Retatrutide. Each is labelled by design below, and each entry says what the paper measured.
- 1 analytical chemistry
- 1 in vitro and animal study
PubMed returns 197 records for the search terms published on the method page (117 of them with a review publication type, 9 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 33 registered studies whose intervention matches the name (32 interventional), checked 5 October 2026.
- Clinical trials are registered and published for retatrutide. Their titles and endpoints state clinical outcomes, so this hub lists only chemistry, analytical and pharmacology papers.
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of Retatrutide?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names retatrutide as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "retatrutide". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Not namedThe WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for Retatrutide?
[1] Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, et al.. Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. Rapid Commun Mass Spectrom. 2026;40:e70179.
LC-HRMS detection and excretion profile of retatrutide in human plasma and urine, for anti-doping analysis.
[2] Ding M, Li X, Wei Y, Wang J, Jiao B, Li C, et al.. Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. iScience. 2026;29:117174.
Compared semaglutide, tirzepatide and retatrutide in human kidney cells and in mouse models of renal fibrosis and ageing.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is Retatrutide covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.